News, Deals & Cases

Recent Financial Market Transactions and Updates.

  • Acquisition of The Medicines Company

    In connection with the acquisition of NASDAQ-listed biopharmaceutical company The Medicines Company for USD 9.7 billion, Novartis AG and Novartis Finance Corporation entered into a USD 7 billion short-term (bridge) credit agreement and completed a USD 5 billion four-tranche SEC-registered bond offering.

    By

    CapLaw

    Read more: Acquisition of The Medicines Company
  • Placement of SGS Shares

    The von Finck family successfully placed 960,000 shares (approx. 12.7%) in SGS SA by way of an accelerated bookbuilding process. The overall transaction volume amounts to CHF 2.3 billion. In light of its long-term investment strategy and planning, the family decided to divest a majority of its stake in SGS.

    By

    CapLaw

    Read more: Placement of SGS Shares
  • Valyo Innovative Capital Market Platform

    Valyo AG, a subsidiary of Raiffeisen Switzerland, has developed an innovative digital platform for issuances of exchange listed bonds geared towards institutional investors. The Valyo platform, intended to be launched in the first quarter of 2020, enables issuers to carry out all steps from the initial registration of a planned issuance through the book building…

    By

    CapLaw

    Read more: Valyo Innovative Capital Market Platform
  • Sunrise terminates SPA with Liberty Global

    On 13 November 2019, Sunrise Communications Group AG announced that it had canceled the share purchase agreement with Liberty Global in connection with its proposed acquisition of UPC Switzerland. 

    By

    CapLaw

    Reference:
    Read more: Sunrise terminates SPA with Liberty Global
  • CRISPR Therapeutics AG public offering of an aggregate 4,887,500 common shares

    On 20 November 2019, CRISPR Therapeutics AG launched its public offering of an aggregate 4,887,500 common shares on Nasdaq raising approximately USD 315.2 million. CRISPR Therapeutics is a leading gene editing company based in Zug, Switzerland, focusing on developing transformative gene-based medicines for serious diseases based on its proprietary CRISPR/Cas9 technology.

    By

    CapLaw

    Reference:
    Read more: CRISPR Therapeutics AG public offering of an aggregate 4,887,500 common shares
  • Jacobs Holding completes the placement of Barry Callebaut Shares

    Jacobs Holding AG successfully placed 550,000 shares (approx. 10%) in Barry Callebaut AG by way of an accelerated bookbuilding process and a simultaneous private placement. Jacobs Holding thus diversified its portfolio while remaining Barry Callebaut’s reference shareholder with a stake of approximately 40%. Jacobs Holding is an investment company founded by entrepreneur Klaus J. Jacobs….

    By

    CapLaw

    Reference:
    Read more: Jacobs Holding completes the placement of Barry Callebaut Shares
  • Canton of Geneva issued a Green Bond

    On 28 November 2019 the Canton of Geneva issued green bonds listed on the SIX Swiss Exchange in an aggregate amount of CHF 660 million. The issuance was made according to the Green Bond Principles published by the International Capital Market Association, and divided into three respective tranches of CHF 175 million with a maturity…

    By

    CapLaw

    Reference:
    Read more: Canton of Geneva issued a Green Bond
  • WisdomTree Issuer X Limited launched one of the world’s first crypto index ETP listed on a regulated stock exchange

    On 3 December 2019, WisdomTree Issuer X Limited was recognized by the SIX Swiss Exchange as a new Exchange Traded Product (ETP) issuer to its trading segment and, launched one of the world’s first crypto index ETP listed on a regulated stock exchange. The ETP is investing in Bitcoin.

    By

    CapLaw

    Reference:
    Read more: WisdomTree Issuer X Limited launched one of the world’s first crypto index ETP listed on a regulated stock exchange
  • Kuros Biosciences completes rights offering

    On 6 December 2019, Kuros Biosciences, a life science company focusing on the development and marketing of orthobiologics, completed a capital increase by way of a rights offering to its shareholders. 36.3% of the shareholders of Kuros Biosciences exercised their subscription rights in the rights offering. 2,818,718 of the remaining shares not subscribed were preferably…

    By

    CapLaw

    Reference:
    Read more: Kuros Biosciences completes rights offering